LipoGalen™ – Our new family of functional lipid-based excipients

9. October 2025

Our innovative polyglycerol esters now have a name – We’re thrilled to Introduce LipoGalen™ as the brand name for our new family of Functional Lipid-Based Excipients.

In the last IOI newsletter, we announced the launch of our new family of functional, lipid-based excipients, the polyglycerol esters. After intensive and dedicated research and development plus countless hours of brainstorming sessions, IOI Oleo GmbH finally unveils something truly special:

LipoGalen™

will be the name of our new brand, which will be making its debut at CPHI Frankfurt.

This launch marks a major milestone for us, and we couldn’t be prouder to share it with you. LipoGalen™ was born out of a deep understanding of the evolving challenges in pharmaceutical formulation. In contrast to common triglycerides, it crystallizes in one stable modification and does not show any polymorphism.

LipoGalen™ offers a versatile, forward-thinking platform designed to empower innovation across a wide range of applications:

  • Rectal and vaginal dosage forms: A novel lipid base that offers new possibilities in the formulation development of such products, with advantages for patients.

  • Controlled-release tablets: Matrix systems that allow precise control over drug-release profiles throughout the shelf-life, because of the superior properties of LipoGalen™ over traditional triglycerides.

  • Solubilization and bioavailability enhancement: Perfect for hot melt extrusion, improving the performance of poorly soluble APIs, while offering the chance of working at reduced processing temperatures compared to the established polymers in this field of application.
  • Taste masking: Effective via hot melt coating, helping improve patient compliance.

  • Lubrication for tableting: Optimized for continuous manufacturing processes.

  • Dermal formulations: Free from paraffins, supporting clean-label, skin-friendly solutions.

  • Advanced delivery systems: Suitable for lipid nanoparticles and nano-emulsions, including inhalation therapies.
  • 3D-printing: Compatible with melt extrusion techniques for personalized medicine and cutting-edge dosage forms.

We warmly invite you to join us at CPHI Frankfurt to discover how LipoGalen™ can elevate your formulation strategies and open up exciting new possibilities in drug delivery.

Let’s shape the future of pharmaceutical development — together.

Share this article!

Dr. Thomas Rillmann

Dr. Thomas Rillmann studied Chemistry at the Technical University of Munich and Pharmacy at the Technical University of Braunschweig, finishing his Ph.D. thesis under the supervision of Prof. Dr. Dr. h.c. Claus Führer. He has more than 25 years of experience in the pharmaceutical industry, mainly working in product development and transfer. He started his professional career at Hexal Pharmaforschung GmbH working on multi-particulate controlled release dosage forms, then joining the STADA group, building up the Pharmaceutical Development Department from 2003 to 2010 and the Product Transfer Department from 2008 to 2009. After a 4-year’s stint in the pharma business segment of BASF SE, he held to two positions in pharmaceutical manufacturing, the last position as a Site Head for Riemser Pharma GmbH. Thomas Rillmann joined IOI Oleo GmbH on January 1st 2023 as Head of Business Development Functional Excipients.

Portrait Dr. Thomas Rillmann